Supplementary Figure 4 from The XPO1 Inhibitor Eltanexor Modulates the Wnt/β-Catenin Signaling Pathway to Reduce Colorectal Cancer Tumorigenesis

Puntos clave

• XPO1 inhibitor eltanexor modulates the Wnt/beta-catenin signaling pathway in colorectal cancer.
• Study shows eltanexor does not change beta-catenin protein expression levels in treated cells.
• Figure S4 illustrates that eltanexor does not affect intracellular localization of beta-catenin.
• Findings suggest potential therapeutic implications of eltanexor without altering key signaling components of tumorigenesis.